2CL Stock Overview A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
BridgeBio Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BridgeBio Pharma Historical stock prices Current Share Price US$25.91 52 Week High US$38.91 52 Week Low US$21.90 Beta 1.06 1 Month Change 5.67% 3 Month Change n/a 1 Year Change n/a 3 Year Change 123.36% 5 Year Change -22.16% Change since IPO 4.69%
Recent News & Updates
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Dec 14
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Approves Attruby™ (Acoramidis) for the Treatment of Adults with ATTR-CM Nov 23
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia Nov 19
Third quarter 2024 earnings released: US$0.86 loss per share (vs US$1.08 loss in 3Q 2023) Nov 14
BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Oct 01
BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024 Aug 31 See more updates
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Dec 14
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Approves Attruby™ (Acoramidis) for the Treatment of Adults with ATTR-CM Nov 23
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia Nov 19
Third quarter 2024 earnings released: US$0.86 loss per share (vs US$1.08 loss in 3Q 2023) Nov 14
BridgeBio Pharma, Inc. Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Oct 01
BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024 Aug 31
BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney Aug 19
Second quarter 2024 earnings released: US$0.39 loss per share (vs US$0.98 loss in 2Q 2023) Aug 02 BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer Jul 23
BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Jun 19
BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia Jun 05
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population May 14
BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024 Apr 28
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Apr 09 BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million. Mar 07
BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million. Mar 06
BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering. Mar 05
Full year 2023 earnings released: US$3.95 loss per share (vs US$3.26 loss in FY 2022) Feb 23
New major risk - Financial position Feb 22
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy Feb 06
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months Feb 03
BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine Jan 11
BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia Dec 14
BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Nov 14
BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9 Oct 10
BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors Sep 27 BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors Sep 26
Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia Sep 07
BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023 Aug 28
New minor risk - Financial position Aug 06
Second quarter 2023 earnings released: US$0.98 loss per share (vs US$0.067 loss in 2Q 2022) Aug 04
Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study Aug 01
Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy Jul 18
BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia Jun 21
Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021) Feb 24
Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1 Dec 24
BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i) Oct 15
BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society Oct 14
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib) Oct 12
BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium Oct 08
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A Sep 21
BridgeBio Pharma, Inc Announces Dosing of First Patient in Phase 1 Trial of BBP-671 Aug 19
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A Aug 11
BridgeBio Pharma, Inc. Announces Positive Interim Results from PROPEL 2 Jul 28
BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc. Receive Positive CHMP Opinion for NULIBRY® (Fosdenopterin) for Treatment of MoCD Type A Jul 27
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers Jun 28
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease Jun 23
BridgeBio Pharma, Inc. Shares Positive Phase 2B Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) Jun 14
BridgeBio Pharma, Inc. and Venthera, Inc. Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations Jun 11
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias May 28 BridgeBio Pharma, Inc. and Phoenix Tissue Repair, Inc Announce Positive Results from Phase 2 Trial of PTR-01 May 21
BridgeBio Pharma, Inc., Annual General Meeting, Jun 22, 2022 May 02
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Apr 04
Sentynl Therapeutics Inc. entered into an asset purchase agreement to acquire Global Rights to NULIBRY from BridgeBio Pharma, Inc. (NasdaqGS:BBIO). Mar 10
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) Jan 28
Independent Director recently bought €264k worth of stock Jan 01 Shareholder Returns 2CL DE Biotechs DE Market 7D -0.8% 1.2% -0.3% 1Y n/a -14.3% 7.0%
See full shareholder returns
Return vs Market: Insufficient data to determine how 2CL performed against the German Market .
Price Volatility Is 2CL's price volatile compared to industry and market? 2CL volatility 2CL Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2CL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2CL's volatility change over the past year.
About the Company BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Show more BridgeBio Pharma, Inc. Fundamentals Summary How do BridgeBio Pharma's earnings and revenue compare to its market cap? 2CL fundamental statistics Market cap €5.19b Earnings (TTM ) -€422.14m Revenue (TTM ) €209.47m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2CL income statement (TTM ) Revenue US$217.77m Cost of Revenue US$2.39m Gross Profit US$215.37m Other Expenses US$654.23m Earnings -US$438.86m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.32 Gross Margin 98.90% Net Profit Margin -201.53% Debt/Equity Ratio -141.1%
How did 2CL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 04:31 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BridgeBio Pharma, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution George Farmer BMO Capital Markets Equity Research Konstantinos Biliouris BMO Capital Markets Equity Research Jason Zemansky BofA Global Research
Show 21 more analysts 